GlassScriptPhysician profile
Yehuda Galili
NPI 1871034074
$17,659.26
in general payments reported to CMS, 2019-2025
29 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.86 · 2022: $119 · 2023: $253 · 2024: $3,674 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $2,781 · Consulting Fee: $2,675 · Education: $194 · Travel and Lodging: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,700.00 |
| Food and Beverage | $2,781.41 |
| Consulting Fee | $2,675.00 |
| Education | $193.94 |
| Travel and Lodging | $176.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $12,975.04 | 2024-2025 | Ojjaara, Blenrep, Jemperli |
| Genzyme Corporation | $2,792.64 | 2024-2025 | |
| Sobi, INC | $315.38 | 2023-2025 | |
| Janssen Biotech, INC. | $265.12 | 2024-2025 | Talvey, Darzalex, Tecvayli |
| Pfizer INC. | $194.80 | 2024-2025 | |
| Kite Pharma, INC. | $185.50 | 2022-2023 | |
| Janssen Research & Development, LLC | $146.14 | 2025 | |
| Beigene USA, INC. | $118.01 | 2023-2024 | Brukinsa |
| Incyte Corporation | $93.95 | 2024 | |
| Recordati_rare_diseases_inc. | $85.00 | 2024 | Sylvant |
| Novartis Pharmaceuticals Corporation | $78.61 | 2025 | |
| Tersera Therapeutics LLC | $50.09 | 2025 | Zoladex |
| Celgene Corporation | $46.13 | 2025 | Reblozyl |
| Astrazeneca Pharmaceuticals LP | $42.69 | 2024-2025 | |
| Apellis Pharmaceuticals, INC. | $41.30 | 2023-2024 | Empaveli |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $32.55 | 2024 | Advate, Iclusig |
| Astellas Pharma US INC | $25.81 | 2025 | Vyloy |
| Taiho Oncology, INC. | $24.76 | 2025 | |
| Servier Pharmaceuticals LLC | $24.32 | 2025 | |
| Pharmacosmos Therapeutics INC. | $23.11 | 2023 | Monoferric |
| Tempus Ai, INC | $21.21 | 2024 | |
| Genentech USA, INC. | $18.19 | 2025 | Polivy |
| E.R. Squibb & Sons, L.L.C. | $16.47 | 2025 | Reblozyl |
| Daiichi Sankyo INC. | $15.94 | 2025 | Enhertu |
| Eisai INC. | $13.64 | 2024 | |
| Avanir Pharmaceuticals, INC. | $12.86 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yehuda Galili listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.